GlassScriptPhysician profile
Rachel A Dugan
NPI 1508133257
$699.54
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $548 · 2022: $152.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $171.23 | 2021-2022 | |
| Abbvie INC. | $116.96 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $53.29 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.41 | 2021 | |
| Phadia US INC. | $36.03 | 2021 | |
| Merck Sharp & Dohme LLC | $35.81 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $33.59 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.82 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $23.66 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.66 | 2022 | |
| Lundbeck LLC | $22.43 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.79 | 2022 | |
| Amarin Pharma, INC. | $19.41 | 2021 | |
| Daiichi Sankyo INC. | $18.47 | 2021 | |
| Glaxosmithkline, LLC. | $17.76 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $13.89 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.33 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Dugan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.